PF3845

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP02317CAS No. ：1196109-52-0Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1196109-52-0	Cat. No.	BCP02317
Name	PF3845
Synonyms	PF-3845;PF 3845;
SMILES
Chemical Name
Formula	C24H23F3N4O2	M. Wt	456.46
Purity	98%	Storage	Store at 4-8°C
Description	PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.).PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modif